Meeting
2012 Breast Cancer Symposium
Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
Authors
Francis Arena
Arena Oncology Associates
Francis Arena , Shinzaburo Noguchi , Kathleen Pritchard , Howard Burris III, Hope Rugo , Michael Gnant , Gabriel Hortobagyi , Luciano Latini , Denise Yardley , Bohuslav Melichar , Katarina Petrakova , Wael Harb , Wentao Feng , Ayelet Cahana , Tanya Taran , Mario Campone , José Baselga , Tarek Sahmoud , David Lebwohl , Martine Piccart-Gebhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A
Track
Risk Assessment, Prevention, Detection, and Screening
Sub Track
Advanced Disease
Clinical Trial Registration Number
NCT00863655
Citation
J Clin Oncol 30, 2012 (suppl 27; abstr 99)
DOI
10.1200/jco.2012.30.27_suppl.99
Abstract #
99
Poster Bd #
A2
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.
First Author: Francesco Perrone
Poster
2017 ASCO Annual Meeting
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).
First Author: Gabriel N. Hortobagyi
Poster
2015 ASCO Annual Meeting
A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25).
First Author: Maysa M. Abu-Khalaf
Poster
2013 ASCO Annual Meeting
BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+ HER2- advanced breast cancer.
First Author: Bent Ejlertsen